Prof. Meral Beksac – The recent developments in the field of bispecific T-cell engagers By efrat|2022-07-28T08:49:55+00:00July 28th, 2022|All|Comments Off on Prof. Meral Beksac – The recent developments in the field of bispecific T-cell engagers Share This Story, Choose Your Platform! FacebookTwitterRedditLinkedInWhatsAppTumblrPinterestVkEmail About the Author: efrat Related Posts Dr. Oluwole Olalekan- Approval of Polatuzumab Vedotin Plus R-CHP in Previously Untreated DLBCL Dr. Oluwole Olalekan- Approval of Polatuzumab Vedotin Plus R-CHP in Previously Untreated DLBCL Dr. Bhagirathbhai Dholaria- Omisirge Allogeneic Cord Blood-Based Cell Therapy Approved to Reduce Risk of Infection Following Stem Cell Transplantation Dr. Bhagirathbhai Dholaria- Omisirge Allogeneic Cord Blood-Based Cell Therapy Approved to Reduce Risk of Infection Following Stem Cell Transplantation Dr. Paula Rodríguez Otero- Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma Dr. Paula Rodríguez Otero- Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma Prof. Christoph Stein Thoeringer- Role of the Gut Microbiome in CAR-T cell Therapy Prof. Christoph Stein Thoeringer- Role of the Gut Microbiome in CAR-T cell Therapy Dr. Doris Hansen- Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium Dr. Doris Hansen- Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium
